{"name":"Mundipharma (China) Pharmaceutical Co. Ltd","slug":"mundipharma-china-pharmaceutical-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Pain","slug":"pain","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"Buprenorphine transdermal patches","genericName":"Buprenorphine transdermal patches","slug":"buprenorphine-transdermal-patches","indication":"Chronic moderate to severe pain","status":"phase_3"},{"name":"OXYCONTIN®","genericName":"OXYCONTIN®","slug":"oxycontin","indication":"Acute postoperative pain","status":"marketed"},{"name":"OxyNorm Capsules","genericName":"OxyNorm Capsules","slug":"oxynorm-capsules","indication":"Moderate to severe acute pain","status":"phase_3"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Morphine Sulfate Sustained-Release Tablet","genericName":"Morphine Sulfate Sustained-Release Tablet","slug":"morphine-sulfate-sustained-release-tablet","indication":"Moderate to severe pain","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"OXN PR tablet","genericName":"OXN PR tablet","slug":"oxn-pr-tablet","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"Buprenorphine transdermal patches","genericName":"Buprenorphine transdermal patches","slug":"buprenorphine-transdermal-patches","phase":"phase_3","mechanism":"Buprenorphine is a partial mu-opioid receptor agonist that binds with high affinity to opioid receptors in the central nervous system to provide analgesia and reduce opioid cravings.","indications":["Chronic moderate to severe pain","Opioid use disorder (maintenance treatment)"],"catalyst":""},{"name":"Morphine Sulfate Sustained-Release Tablet","genericName":"Morphine Sulfate Sustained-Release Tablet","slug":"morphine-sulfate-sustained-release-tablet","phase":"phase_3","mechanism":"Morphine sulfate works by binding to opioid receptors in the brain and spinal cord, producing analgesia and altering emotional responses to pain.","indications":["Moderate to severe pain","Severe pain in cancer patients"],"catalyst":""},{"name":"OXN PR tablet","genericName":"OXN PR tablet","slug":"oxn-pr-tablet","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"OXYCONTIN®","genericName":"OXYCONTIN®","slug":"oxycontin","phase":"marketed","mechanism":"OxyContin is a medication that works by binding to opioid receptors in the brain, altering the way the body perceives pain.","indications":["Acute postoperative pain","Chronic Pain with Opioid Tolerance","Severe pain"],"catalyst":""},{"name":"OxyNorm Capsules","genericName":"OxyNorm Capsules","slug":"oxynorm-capsules","phase":"phase_3","mechanism":"OxyNorm is an immediate-release oral formulation of oxycodone, a mu-opioid receptor agonist that binds to opioid receptors in the central nervous system to produce analgesia and other opioid effects.","indications":["Moderate to severe acute pain","Breakthrough pain in opioid-tolerant patients"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxNTWo1M0NMT1pzY1pDcjN1SGJrTmZmcE8xWTZGMVlEUTlSUDU4TzVFUUNUSmx1WjNSRGQ5VWh5VGhQRERlLU5qWnlRRF9GVzkydUpkMldUOTFfZ1B2S0dtLXpfSVZUQmhjeDRWVE01c2pPMjlKVjRRNzJtR21FV1RhbmZTTjkwV05JVDg2VnhZamFlZVM3T3hKOEFnQ2dLTXc?oc=5","date":"2024-09-17","type":"earnings","source":"Finance Uncovered","summary":"Revealed: How the Sackler family’s opioid empire continues to make hundreds of millions of dollars in profits around the world - Finance Uncovered","headline":"Revealed: How the Sackler family’s opioid empire continues to make hundreds of millions of dollars in profits around the","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxOVVVmOXZ3akk4TnRJeUxxejF0cFBQNXp6cGJYX0M4ZlBONGZKaGxUeW9UT0pOSjFnc3R5SzhpNHpZaks1dHhvSnBSQWdlSWhhY0pWUTZ3VTdEenFESFFxLWR4eFhSMi1FTEZXOV9nQTZiLXNsR2EwR2RFbW1tUWMwX2NYdlZ0SGlmWUh2MVR3c2UxY0YyZHAtd0dNQXhveXRlUzB3YndOdGRZRU42RlZrVzBQQ1pyYUhLUzZR?oc=5","date":"2024-09-17","type":"pipeline","source":"The Examination","summary":"In the US, opioid-maker Purdue is bankrupt. Its global counterparts make millions. - The Examination","headline":"In the US, opioid-maker Purdue is bankrupt. Its global counterparts make millions.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxOS2NDYl9nRUZuY0tCVnI4NE9uNHVkZUltaDlPQktMN1FMdEQtcjRUVXQ1dW1KakRlbU1FTEppVmFZekVzRThfZ0R0bnFSQjAwT1dXeElIaGlMWTM0REhZUk9EUXRPd25xdEZ1Vl9xNHNaM1ZPcnV4VThMQk92bFo1ODB6V05fQjk0RU5NaGVaanpXSkN5dHAyaTFJNEhfT3ZoYlZHbHlWN2JlX1hoeDR3UmJMU0c?oc=5","date":"2023-08-01","type":"deal","source":"Nasdaq","summary":"Mundipharma International Corporation Limited, Mundipharma Medical Company, and Acrotech Biopharma Inc. Enter Agreement to Transfer License of FOLOTYN® (Pralatrexate) in China to CASI Pharmaceuticals ","headline":"Mundipharma International Corporation Limited, Mundipharma Medical Company, and Acrotech Biopharma Inc. Enter Agreement ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxNZk41dFVBbV9HYlZiaC1LNDBadTk2QlRHdlBCOUN1Y2hSYnNEZ0VtVzU4ZlNWbXcwcU9RaTExTGNNQzMzV2JQRkFaWVdlS09IVGlNYkFOZ05mR2wtZWNIVEx5R1RsUVVucTJROUFITk5oTElyS2lHZ2NFWm0takZnWlN2bXhvMm45SWNKUnVsMzNyQlpaR1Y5SlVHSU02S1FnUEt2Tk0ySGlVY2tvY0kxLWFnalk4UQ?oc=5","date":"2023-07-20","type":"pipeline","source":"Bloomberg.com","summary":"Billionaire-Backed Mundipharma Weighs Reviving China Sale, Sources Say - Bloomberg.com","headline":"Billionaire-Backed Mundipharma Weighs Reviving China Sale, Sources Say","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxOSUFURDJOc21GU2FhanktU1FMTkM4T2M2ei1QSWpUTVdaT3ZkMktfUTdyT0FCSkd0dmtsVzIxTWQycnQ0VUktdkRublRSNjdtSy1tNDFlTUFKNFJUbFFreUU5V1BoVG5hSEpYRHc3c2ItS1dtR1FYdVNYWjNvck1sMnJR?oc=5","date":"2023-06-26","type":"deal","source":"Pharmaceutical Technology","summary":"iNova to acquire Mundipharma’s consumer healthcare brands - Pharmaceutical Technology","headline":"iNova to acquire Mundipharma’s consumer healthcare brands","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxNN1Y4cjFGcUdoR1VnbU5qQ0hXVTZzUHJxbWdoQzFPUWRJMHlBVld5Z0NSYXpBSFlaWnVxUWlLWEZUTTF0TlhFWDllMFkxZF9ZLVFoQjh3dkNWeVU5MFhwM09HYTF5ZzhtUDdFUmNJcEtlb24yTFZaQk1CUXIwd1pBQWxfeThVSEFiSXNnZnVaZ1RHZkpkbUp4M0hZaFVYV2NVTXZaOVYtb0NpaVY4TGRUNDYxQ3U?oc=5","date":"2020-01-13","type":"pipeline","source":"Bloomberg.com","summary":"Sackler-Owned Mundipharma Said to Tap Deutsche Bank for Sale - Bloomberg.com","headline":"Sackler-Owned Mundipharma Said to Tap Deutsche Bank for Sale","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxOQXRuLVMxWVBoRE9wMEVDclpEb0hpa0piYk00NlJxYW5FTHlLN1lzdVlCcEZGWjZ2ajB2TGdRZ1I2eDdvNFE4UV82a25MVDZ6SlNnNlVDS0VLUkxadG5pZzZoQmljZE5FcS0zc2M0dFdsNENUTzh3Y0lHMElmZndNUlh1YkNzTUtlX1RoSW9YT19PSXFpR21BRHhpNnpSSjluQXpibDZEUnIyUHZ0ckJ6dWREMGl3M2o5?oc=5","date":"2019-11-20","type":"pipeline","source":"nypost.com","summary":"Sackler family company caught using same dirty tricks to peddle Oxy in China - nypost.com","headline":"Sackler family company caught using same dirty tricks to peddle Oxy in China","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxQckU0MjlQdk5UZ3NoSVc0RllrZ2p1UTg4aklfdDdvdklQRHZBbXB4WjZCUS1nR2YtU3hyTTItU0hqbzN1TWNNeGlYZUVtNXRmR0FnQ2FydXJNTUt3S0VGeHRFQlF6SUV2dEEtdk9SaWtTSGJ4ZzJ6b0ZTRW1mSzlSaFNjQjVUVEYwbE9ZWXhQQjBEQUNkWHpERE9GQ2h3amhTbFlHOTFlS01LZmpqNWhGYdIBsAFBVV95cUxPXzFVMDVnT3NuVmU1VnQtd3A0WGp3RWtXcmxQT0RydlZCU2VWb2tSQmN0N1BTcGdpTDdJWE9BVHpveXpweWR3bUdsamN6ZkpzNnIzajA3bm9mbDVSM2dFOGFSaUtranFMOUlvUEJEVmNuN3R4aEJrY1ZLQ0xSV2tuYm1RclBfelhEUHdRMEF2T3lPcFNmRmE4VnluTVNhMGlzakpxRnk5WEFjcWd0WWlidQ?oc=5","date":"2019-11-20","type":"pipeline","source":"South China Morning Post","summary":"Chinese firm accused of using fake doctors to drive OxyContin sales - South China Morning Post","headline":"Chinese firm accused of using fake doctors to drive OxyContin sales","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxOaUZZSXB6a1hLTDFtMGpCNjc3QS1ZMFdSSjRoVjNzUldsaTJzTG5GMGludGtFUERPeUJuR09tZUpObXNUdS1pdkdYcWRRdEoxX1pWclE0TzVNbkZPZWQ5eWRhM1BCZmh3VU11dF9WY1oxdXBqZzBSVmE1WmZ0aXVNN1luWFVfNFhScWxkWGJrcHl4X2E1cGthU0Z4Znh6TmRyTkFXVDlROEFaZ2VMQU14Ull3VzVyRUZUVW4ycHVnRQ?oc=5","date":"2018-12-04","type":"regulatory","source":"BioSpectrum Asia","summary":"Helsinn, Mundipharma China Pharmaceutical announce tha approval of ALOXI - BioSpectrum Asia","headline":"Helsinn, Mundipharma China Pharmaceutical announce tha approval of ALOXI","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxPMjJEZXBKUE8weTlCOGRycWFNcTY5VVV4MWYtcHVSaFhHT3NDLWNZNnRiLTBxd0JVdFFrX0h0a0xIVE4yR09MNmFUQmxNTTRYeWVyVDFYN2pWdTdRS1cyU2pkMnl4YlVUWEQ1US1rcUtfRF9FaDhpUnBFRDFkOVFvLV82SlBUZUtEdndkMGN5WTdSSUo0eWRVb2VtRVdxX0twYzRVeg?oc=5","date":"2018-01-16","type":"pipeline","source":"Pharmafile","summary":"Mundipharma signs Chinese licensing and distribution agreement with Grünenthal - Pharmafile","headline":"Mundipharma signs Chinese licensing and distribution agreement with Grünenthal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxNRkdtNnBKblpfSE9oenlDQ1M2YWNiNEJIZmFuXzZaNm1laG5uNnhicHhYYnE4SWxueWd5YzU5VEFESXNHY3U0a1k4ZW5xa21IcXdIeERZVm9FWGFNVVhZcFRxdEFSYVg1clIyOF9GbVVwMlljXzZZazdaYXJVVkFxem5QcVE2OHFYTU5raC1qQkRHcGR5YVFCRGhqdWJWalVKYlNmVlpqcXMxWmowWUZNMTFMZnloQWp6RGI3QtIBvAFBVV95cUxNd1JmTkxXUTE5Q3ctdTU0aEphM1B5U054UjZVYW9Jd3BSV05tZHhjNnNnNDdXM0trZEZHOWtTOEc0NFRUSWlJTW5rejlxckZIS0VPX2c5V3dmd2wzV242M0hyUkNwZ3VsTGZEQm5VbVZzemYzcFR1eU83azNVMWVMVG15Wk1WTUVvSzBTQ1hlbU1ab1gzejliVUR0ZU5idklWMzhsS0p5SHlValRDTlZFTmNtVHhwRUdPXzhBZQ?oc=5","date":"2016-12-19","type":"pipeline","source":"South China Morning Post","summary":"China sales boom for painkiller at centre of US opioid addiction - South China Morning Post","headline":"China sales boom for painkiller at centre of US opioid addiction","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgJBVV95cUxPSVFJZjFSTkYxSW5JejVPTTNXbzFvVlhzaDZ5N0gxaUdxZ2prRFlxbTQ4Z0hzN1JCcGcwX2hEWjdycjFGMG9KYXIxMF9ERms4blVJQURvMmlUNzYxcTlyMkF1TDRlVkJZSTcyT0J4OTRmeTZiUm0yWF85dFhmMjVpLW8xQ0lSdHl1NTJsem92dG9USWJiMzkwUGVxY2NiV1k5bFJWbzlBWWJTd19WVmVFcThDSHlEc1hXSjFFYVU5TWZxb3RoX0VDU29EeE1iMXNxQ0JFcW5oR1BHd3psR2l2YXpiSzZ6elA4ME9Mc2FINDVwTWlYZTkzNU9aQzF0QlFhVW5VcERRM3IxTkNUdmIwRVZQWUpCT1BUSVE?oc=5","date":"2016-05-15","type":"deal","source":"prnewswire.com","summary":"Mundipharma and Purdue Pharma Expand Pain Pipeline with New Deal for First-in-Class Sigma-1 Antagonist (S1A or MR309/E-52862) from ESTEVE - prnewswire.com","headline":"Mundipharma and Purdue Pharma Expand Pain Pipeline with New Deal for First-in-Class Sigma-1 Antagonist (S1A or MR309/E-5","sentiment":"neutral"}],"patents":[],"drugCount":5,"phaseCounts":{"phase_3":3,"phase_1":1,"marketed":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}